Non-invasively aids in the detection, staging, and monitoring of the severity of liver fibrosis for hepatitis C virus (HCV) patients.


For hepatitis C (HCV) patients, we offer the PROMETHEUS FIBROSpect HCV test, which is a laboratory-developed test that aids in in the detection, staging, and monitoring of liver fibrosis. The simple blood test is noninvasive and provides a quantitative fibrosis score to help physicians risk stratify and monitor patients.

  • Differentiates between F0-F1 and F2-F4 liver fibrosis1
  • Validated with samples from 348 biopsy-confirmed HCV patients1

* In a study population of 696 clinically diagnosed HCV patients with liver fibrosis, 348 patient serum samples were used for training and 348 patient serum samples were used for validation.

** At a FIBROSpect HCV Index of 42, the sensitivity and specificity for differentiating F0-F1 from F2-F4 were 82% and 71%, respectively, on the validation samples (n = 348).

***Performance in differentiating F0-F1 from F2-F4 on validation samples (n = 348).


Staging of Liver Fibrosis in HCV Patients is Critical

American Association for Study of Liver Disease (AASLD) and Infectious Disease Society of America (IDSA) 2017 guidelines highlight the benefits of initiating therapy in HCV patients with lower-stage liver fibrosis2:

  • “Initiating therapy in patients with lower-stage fibrosis augments the benefits of SVR [sustained virologic response]”
  • “Treatment delay may decrease the benefit of SVR”
  1. Data on file. Prometheus Laboratories Inc.
  2. When and in whom to initiate HCV therapy. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Web site. Last updated July 6, 2016. Accessed July 24, 2017.

The FibroSPECT tests are laboratory-developed tests that were developed and validated under Federal CLIA laboratory guidelines, and are performed exclusively by Prometheus Laboratories Inc.
These tests have not been cleared or approved by the US FDA. The tests are used for clinical purposes and should not be regarded as investigational or for research. Prometheus Laboratories is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing and is accredited by the College of American Pathologists (CAP).
This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.